# FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty

> **NCT03276143** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 813 (actual)

## Conditions studied

- Knee Arthroplasty, Total

## Interventions

- **DRUG:** Enoxaparin
- **DRUG:** Apixaban
- **DRUG:** BAY1213790

## Key facts

- **NCT ID:** NCT03276143
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-21
- **Primary completion:** 2018-08-20
- **Final completion:** 2019-01-02
- **Target enrollment:** 813 (ACTUAL)
- **Last updated:** 2020-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03276143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03276143, "FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03276143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*